- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05848713
Antitrombotische therapie om klinische complicaties bij buiten het ziekenhuis verworven pneumonie te verbeteren (ATTACC-CAP)
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The global incidence of hospitalization due to CAP is high and associated with substantive morbidity and mortality. Thrombotic complications - including venous, arterial, and possibly microvascular - occur commonly in hospitalized patients across many etiologies of CAP. Poor outcomes may be mediated by both inflammatory and thrombotic processes leading to respiratory, cardiac, and other end organ dysfunction. There are currently no established therapies that modify the potentially maladaptive immunothrombosis pathway in CAP.
Therapeutic-dose anticoagulation with heparin reduces disease progression and mortality in non-critically ill patients hospitalized with COVID-19 with an acceptable safety profile. COVID-19 shares pathogenic features, including activation of the inflammatory and coagulation cascades, with other pneumonias. Whether therapeutic-dose heparin confers similar clinical benefits in non-COVID-19 CAP is unknown.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Chantale Pineau
- Telefoonnummer: 2042353223
- E-mail: attacc.cap@umanitoba.ca
Studie Locaties
-
-
Espírito Santo
-
Serra, Espírito Santo, Brazilië, 29166-828
- Werving
- Hospital Estadual Dr. Jayme Santos Neves
-
Contact:
- Marcus Matos, MD
-
Hoofdonderzoeker:
- Marcus Matos, MD
-
Vila Velha, Espírito Santo, Brazilië
- Werving
- Hospital Evangelico de Vila Velha
-
Contact:
- Joao Moraes Junior, MD
-
Hoofdonderzoeker:
- Joao Moraes Junior, MD
-
Hoofdonderzoeker:
- Guiherme Fonseca, MD
-
-
Estado de Bahia
-
Itabuna, Estado de Bahia, Brazilië
- Voltooid
- Santa Casa de Misericordia de Itabuna
-
-
Federal District
-
Brasília, Federal District, Brazilië
- Voltooid
- Hospital Brasilia
-
Brasília, Federal District, Brazilië
- Voltooid
- Instituto de Cardiologia e Transplantes do Distrito Federal
-
-
Goiás
-
Goiânia, Goiás, Brazilië
- Werving
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
-
Contact:
- Sandra Nivea dos Reis Saraiva, MD
-
Hoofdonderzoeker:
- Sandra Falcao, MD
-
Goiânia, Goiás, Brazilië
- Werving
- Hospital Ruy Azeredo
-
Contact:
- Rafael Bastos, MD
-
Hoofdonderzoeker:
- Rafael Bastos, MD
-
Goiânia, Goiás, Brazilië
- Werving
- Instituto Goiano de Oncologia e Hematologia - INGOH
-
Contact:
- Mayler Santos, MD
-
Hoofdonderzoeker:
- Mayler Santos, MD
-
-
Mato Grosso do Sul
-
Campo Grande, Mato Grosso do Sul, Brazilië
- Werving
- Hospital São Julião
-
Contact:
- Maurício Pompílio Pompílio, MD
-
Campo Grande, Mato Grosso do Sul, Brazilië
- Werving
- Santa Casa de Campo Grande
-
Contact:
- Eduardo Calvoso, MD
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazilië
- Voltooid
- Hospital Felicio Rocho
-
Belo Horizonte, Minas Gerais, Brazilië
- Voltooid
- NUPEC-Orizonti
-
Belo Horizonte, Minas Gerais, Brazilië
- Werving
- Santa Casa de Misericórdia de Belo Horizonte
-
Contact:
- Claudio Dornas, MD
-
Uberaba, Minas Gerais, Brazilië
- Werving
- Hospital das Clínicas da Universidade Federal do Triângulo Mineiro
-
-
Paraná
-
Campo Largo, Paraná, Brazilië, 83606-177
- Werving
- Hospital do Rocio
-
Contact:
- CESAR DUSILEK, MD
-
Curitiba, Paraná, Brazilië
- Werving
- Hospital Santa Cruz
-
Contact:
- Marcelo Carneiro, MD
-
Hoofdonderzoeker:
- Marcelo Carneiro, MD
-
Curitiba, Paraná, Brazilië
- Voltooid
- PUCPR
-
-
Rio Grande do Sul
-
Lajeado, Rio Grande do Sul, Brazilië
- Werving
- Hospital Bruno Born
-
Contact:
- Lucas Mallmann, MD
-
Hoofdonderzoeker:
- Lucas Mallmann, MD
-
Passo Fundo, Rio Grande do Sul, Brazilië
- Werving
- Hospital Sao Vicente de Paulo
-
Contact:
- Alexandre Tognon, MD
-
Hoofdonderzoeker:
- Alexandre Tognon
-
Porto Alegre, Rio Grande do Sul, Brazilië
- Werving
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Paulo Dalcin, MD
-
Hoofdonderzoeker:
- Paulo Dalcin, MD
-
Santa Maria, Rio Grande do Sul, Brazilië
- Voltooid
- Hospital Universitario de Santa Maria
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brazilië
- Werving
- Hospital Clementino Fraga Filho - UFRJ
-
Contact:
- Fernanda Mello
-
-
Santa Catarina
-
Criciúma, Santa Catarina, Brazilië
- Werving
- Hospital Sao Jose
-
Contact:
- Felipe Pizzol, MD
-
Hoofdonderzoeker:
- Felipe Pizzol, MD
-
-
South Carolina
-
São José, South Carolina, Brazilië
- Voltooid
- Hospital Regional Homero Miranda Gomes
-
-
São Paulo
-
Botucatu, São Paulo, Brazilië
- Werving
- UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
-
Contact:
- Suzana Erico Tanni, MD
-
Hoofdonderzoeker:
- Suzana Erico Tanni, MD
-
Bragança Paulista, São Paulo, Brazilië
- Werving
- Hospital Universitario Sao Francisco na Providencia na Deus
-
Contact:
- Gustavo Mamprin, MD
-
Hoofdonderzoeker:
- Gustavo Mamprin, MD
-
Campinas, São Paulo, Brazilië
- Werving
- IPECC
-
Contact:
- Jose Francisco Kerr Saraiva, MD
-
Hoofdonderzoeker:
- Jose Francisco Kerr Saraiva, MD
-
Campinas, São Paulo, Brazilië, 13083-190
- Werving
- Fundação Centro Médico de Campinas
-
Contact:
- Otavio Coelho, MD
-
Hoofdonderzoeker:
- Otavio Coelho, MD
-
Osasco, São Paulo, Brazilië
- Werving
- CiTen - Centro Hospital Municipal Antonio Giglio
-
Contact:
- Enrico Fortunato, MD
-
Hoofdonderzoeker:
- Enrico Fortunato, MD
-
Presidente Prudente, São Paulo, Brazilië
- Werving
- Hospital Regional de Presidente Prudente
-
Contact:
- Luis Felipe Pires, MD
-
Hoofdonderzoeker:
- Luis Felipe Pires, MD
-
Ribeirão Preto, São Paulo, Brazilië
- Nog niet aan het werven
- Hospital Estadual de Serrana
-
Contact:
- Marcos Borges, MD
-
Hoofdonderzoeker:
- Marcos Borges, MD
-
São Paulo, São Paulo, Brazilië, 05403-010
- Werving
- HCFMUSP
-
Contact:
- Ludhmila Hajjar, MD
-
Hoofdonderzoeker:
- Ludhmila Hajjar, MD
-
São Paulo, São Paulo, Brazilië, 02189-010
- Werving
- Hospital Nipo-Brasileiro
-
Contact:
- Jose Victor Krasner Schubsky, MD
-
São Paulo, São Paulo, Brazilië
- Voltooid
- Santa Casa de Misericordia de Sao Paulo
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Werving
- Foothills Medical Centre - Alberta Health Services
-
Contact:
- Deepa Suryanarayan, MD
- Telefoonnummer: 4039448167
- E-mail: dsuryana@ucalgary.ca
-
Hoofdonderzoeker:
- Deepa Suryanarayan, MD
-
Grande Prairie, Alberta, Canada, T8V 4B1
- Nog niet aan het werven
- Grand Prairie Regional Hospital
-
Contact:
- Tafi Madzimure, MD
-
Hoofdonderzoeker:
- Tafi Madzimure, MD
-
-
British Columbia
-
Nanaimo, British Columbia, Canada
- Werving
- Nanaimo Regional General Hospital
-
Contact:
- Alistair Teale, MD
-
Hoofdonderzoeker:
- Alistair Teale, MD
-
Penticton, British Columbia, Canada
- Nog niet aan het werven
- Penticton Regional Hospital
-
Contact:
- Teresa Rodriguez, MD
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Werving
- Vancouver General Hospital
-
Hoofdonderzoeker:
- Ted Steiner, MD
-
Contact:
- Ted Steiner, MD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Werving
- St. Boniface General Hospital
-
Contact:
- Vi Dao, MD
-
Hoofdonderzoeker:
- Terry Wuerz, MD
-
Hoofdonderzoeker:
- Vi Dao, MD
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Werving
- Health Sciences Center Winnipeg
-
Contact:
- Brett Houstin, MD
-
Winnipeg, Manitoba, Canada
- Werving
- Grace General Hospital
-
Contact:
- Sylvain Lother, MD
- E-mail: sylvain.lother@umanitoba.ca
-
Hoofdonderzoeker:
- Sylvain Lother, MD
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1C 5S7
- Werving
- Memorial University
-
Contact:
- Peter Daley, MD
-
Hoofdonderzoeker:
- Peter Daley, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 2H3
- Werving
- Health Sciences North Research Institute
-
Contact:
- Pandma Puranam, MD
-
Hoofdonderzoeker:
- Pandma Puranam, MD
-
Greater Sudbury, Ontario, Canada
- Werving
- Health Sciences North ResearchInstitute (HSNRI)
-
Contact:
- Pandma Puranam, MD
-
Hamilton, Ontario, Canada
- Werving
- Hamilton Health Sciences
-
Contact:
- Alison Fox-Robichaud, MD
-
Hoofdonderzoeker:
- Alison Fox-Robichaud, MD
-
Hamilton, Ontario, Canada
- Werving
- Hamilton Health Sciences - Juravinski
-
Hoofdonderzoeker:
- Dominik Mertz, MD
-
Hoofdonderzoeker:
- Bram Rochwerg, MD
-
Contact:
- Bram Rochwerg, MD
-
Markham, Ontario, Canada, L3P 7P3
- Werving
- Markham Stouffville Hospital
-
Hoofdonderzoeker:
- Paul Lee, MD
-
Contact:
- Paul Lee, MD
-
Hoofdonderzoeker:
- Janet Nguyen, MD
-
Ottawa, Ontario, Canada
- Werving
- The Ottawa Hospital
-
Contact:
- Lana Castellucci, MD
-
Ottawa, Ontario, Canada
- Werving
- Hôpital Montfort
-
Contact:
- Marc Carrier, MD
-
Saint Catherines, Ontario, Canada, L2S 0A9
- Werving
- Niagara Health System - St Catharines Site
-
Contact:
- Aidan Findlater, MD
- E-mail: Aidan.Findlater@niagarahealth.on.ca
-
Hoofdonderzoeker:
- Aidan Findlater, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Sunnybrook Health Sciences Centre
-
Contact:
- Jonathan Zipursky, MD
-
Hoofdonderzoeker:
- Jonathan Zipursky, MD
-
Toronto, Ontario, Canada
- Nog niet aan het werven
- St. Michael's Hospital
-
Contact:
- Michael Colacci, MD
-
-
Quebec
-
Montreal, Quebec, Canada
- Werving
- Jewish General Hospital
-
Contact:
- Susan Khan, MD
-
Contact:
- Vicky Tagalakis, MD
-
Montreal, Quebec, Canada, H4A3J1
- Werving
- McGill University Health Centre
-
Contact:
- Emily Gibson McDonald, MD, MSc
-
Montreal, Quebec, Canada
- Werving
- Centre Hospitalier de l'université de Montréal (CHUM)
-
Contact:
- Emmanuelle Duceppe, MD
-
Québec, Quebec, Canada
- Werving
- CHU de Quebec-University Laval
-
Contact:
- Alexis Turgeon, MD, MSc
-
Québec, Quebec, Canada
- Werving
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
Contact:
- Francois Lallouche, MD
-
Sherbrooke, Quebec, Canada
- Werving
- Centre Hospitalier Universitaire de Sherbrooke
-
Hoofdonderzoeker:
- Francois Lamontagne, MD
-
Contact:
- Francois Lamontagne, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0W5
- Werving
- Regina General Hospital
-
Hoofdonderzoeker:
- Payam Dehghani, MD
-
Contact:
- Payam Dehghani, MD
-
Saskatoon, Saskatchewan, Canada
- Nog niet aan het werven
- University of Saskatchewan
-
Contact:
- Geroffrey Shumailak, MD
-
-
-
-
Mexico City
-
Mexico City, Mexico City, Mexico
- Werving
- Hospital General Regional 1. Carlos MacGregor Sánchez Navarro
-
-
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Contact:
- Jonathan Paul, MD
-
-
Louisiana
-
Jefferson, Louisiana, Verenigde Staten, 70121
- Werving
- Ochsner Clinic
-
Contact:
- Derek Vondehaar, MD
-
-
Maine
-
Portland, Maine, Verenigde Staten, 04102
- Werving
- Maine Medical Centre
-
Contact:
- Daniel Meyer, MD
-
Hoofdonderzoeker:
- Daniel Meyer, MD
-
-
Michigan
-
Dearborn, Michigan, Verenigde Staten, 48128
- Voltooid
- Henry Ford Health System
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Werving
- Cooper University Health Care
-
Contact:
- Adam Green, MD
-
Hoofdonderzoeker:
- Adam Green, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- Medical College of Wisconsin
-
Contact:
- Alisha Sharma, MD
-
Hoofdonderzoeker:
- Alisha Sharma, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients ≥18 years of age
-
Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
- Radiographic evidence of new or worsening infiltrate
- One or more of the following signs and/or symptoms of lower respiratory tract infection
i. New or increased cough or sputum production ii. Fever of > 37.8C or temperature < 36C iii. WBC > 11 x 109/L or < 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
-
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
-
Hospital admission anticipated to last ≥72 hours from randomization
Exclusion Criteria:
-
Suspected or confirmed active COVID-19 infection
-
Hospital admission for >72 hours prior to randomization
-
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
-
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
-
Patients for whom the intent is to not use pharmacologic thromboprophylaxis
-
Patients with an independent indication for therapeutic-dose anticoagulation
-
Patients with a contraindication to therapeutic-dose anticoagulation, including:
- Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
- History of an inherited or acquired bleeding disorder
- Cerebral aneurysm or mass lesions of the central nervous system
- Ischemic stroke within 3 months of hospital admission
- Gastrointestinal bleeding within 3 months of hospital admission
- Platelet count <50 x109/L OR INR >2.0 OR hemoglobin <80 g/L at the time of screening
- Other physician-perceived contraindications to therapeutic anticoagulation
-
History of heparin induced thrombocytopenia (HIT) or other heparin allergy
-
Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
-
Patients in whom imminent death is anticipated
-
Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
-
Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Therapeutic-Dose Heparin
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization. |
Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient. Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement. |
|
Geen tussenkomst: Usual Care
Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Ordinal endpoint reflecting survival
Tijdsspanne: 30 days
|
Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications. |
30 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Allen leiden tot sterfte
Tijdsspanne: 30 dagen, 90 dagen en 180 dagen
|
30 dagen, 90 dagen en 180 dagen
|
|
|
Bleeding events
Tijdsspanne: 14 days
|
Number of participants with major bleeds as defined by the ISTH definition. |
14 days
|
|
HIT events
Tijdsspanne: 14 days
|
Number of participants with laboratory confirmed heparin induced thrombocytopenia (HIT) |
14 days
|
|
Thrombotic events
Tijdsspanne: 30 days and 90 days
|
Number of participants with deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke |
30 days and 90 days
|
|
Invasive mechanical ventilation
Tijdsspanne: 30 days
|
Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization |
30 days
|
|
Hospital-free days
Tijdsspanne: 30 days, 90 days, and 180 days
|
Days alive outside hospital |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Tijdsspanne: 30 days, 90 days, and 180 days
|
Using the EQ-5D-5L instrument |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Tijdsspanne: 30 days, 90 days, and 180 days
|
Using the Clinical Frailty Scale instrument |
30 days, 90 days, and 180 days
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Patrick Lawler, MD, University Health Network and McGill University
- Hoofdonderzoeker: Sylvain Lother, MD, University of Manitoba
- Hoofdonderzoeker: Alexis Turgeon, MD, L'Universite Laval
- Hoofdonderzoeker: Ryan Zarychanski, MD, University of Manitoba
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ATTACC-CAP
- OZM-129 (Andere identificatie: Ozmosis Research Inc.)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .